Oxford Vacmedix
Oxford Vacmedix is a biotechnology company focused on developing therapeutic agents for cancer treatment based on Recombinant Overlapping Peptides (ROP). Established in 2012 as a spinout from Oxford University, it works on immunotherapy solutions.
- Immunotherapy development
- Personalised cancer vaccines
- Recombinant Overlapping Peptides (ROP)
- Diagnostics for anti-microbial resistance
Locations
Digital Popularity
Social Media
LinkedIn415 Followers
Competitors
SpyBiotech is a clinical stage company that utilises its unique protein superglue technology to develop vaccines against infectious diseases and cancer.
PACE is a pioneering partnership focused on addressing the global threat of antimicrobial resistance (AMR) through funding and supporting early-stage antimicrobial drug and diagnostics projects.
GeneOmics Solutions is dedicated to early diagnosis and treatment through the integration of multi-omics data for precision medicine.
Company Details
Oxford Vacmedix is operated by Oxford Vacmedix UK Limited and is a Active company incorporated on 16 March 2012 with the registered office located in Oxford, Oxfordshire. Oxford Vacmedix UK Limited was registered 13 years ago.
Status
Active
Size
Micro
Directors
9
Age
13 years old
Employees
6
Turnover
Unreported
Total Assets
£810K
Cash in Bank
£248K
Total Liabilities
-£429K